StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer In-Process R&D (IPR&D) by Year

In-Process R&D (IPR&D) — Indefinite-lived carrying amount ($M) ($M)

Pfizer In-Process R&D (IPR&D): $21,760M in FY2025, up 15.2% from a year earlier.

Latest, FY2025
21,760
Period ended Dec 31, 2025
Change on a year earlier
+15.2%
18,893 in FY2024
History
11 years
Since FY2015
Sources
11
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Goodwill & Other Intangible Assets Footnote.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedIn-Process R&D (IPR&D) — Indefinite-lived carrying amount ($M) ($M)Year on yearSource
FY2025Dec 31, 202521,760+15.2%Form 10-Q (filed 2026-08-04) ↗
FY2024Dec 31, 202418,893-18.5%Form 10-K (filed 2026-02-26) ↗
FY2023Dec 31, 202323,193+104.2%Form 10-K (filed 2025-02-27) ↗
FY2022Dec 31, 202211,357+267.3%Form 10-K (filed 2024-02-22) ↗
FY2021Dec 31, 20213,092-2.6%Form 10-K (filed 2023-02-23) ↗
FY2020Dec 31, 20203,175-46.4%Form 10-K (filed 2022-02-24) ↗
FY2019Dec 31, 20195,919+172.6%Form 10-K (filed 2021-02-25) ↗
FY2018Dec 31, 20182,171-58.6%Form 10-K (filed 2020-02-27) ↗
FY2017Dec 31, 20175,249-48.0%Form 10-K (filed 2019-02-28) ↗
FY2016Dec 31, 201610,101+762.6%Form 10-K (filed 2018-02-22) ↗
FY2015Dec 31, 20151,171–Form 10-K (filed 2017-02-23) ↗

Cite this data

StockData. (2026). Pfizer In-Process R&D (IPR&D) ($M), annual FY2015–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/iprd-only

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.